Fredag 14 Mars | 13:03:48 Europe / Stockholm
2025-03-07 08:40:24

Antibiotic resistance is a growing global crisis, increasing the urgency for effective treatments. While Medivir now focuses on cancer therapies, it has a legacy in antimicrobial research. This was highlighted by Infex Therapeutics licensing agreement with Venus Remedies Ltd for the development of MET-X in India - a compound developed from a research program that Medivir outlicensed in 2017. We reached out to Medivir's CEO Jens Lindberg for a comment.

Read the interview with Jens Lindberg at biostock.se:

https://www.biostock.se/en/2025/03/medivirs-ceo-i-am-proud-to-see-our-research-contribute-to-a-global-solution/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/